In a specialized session attended by the Managing Director of the Medical Procurement Organization, senior executives, and independent experts, the plasma investment initiative—proposed by Helal Iran Medical Devices Company—was formally introduced and entered the phase of operational, financial, and infrastructural evaluation.
According to the Public Relations and
International Affairs Unit of the MPO, the session to assess the plasma
investment project was held on Saturday, September 13, 2025, at the
Organization’s headquarters. During the meeting, Dr. Sobhani, Managing Director
of Helal Iran Medical Devices Company—a subsidiary of the Medical Procurement
Organization—presented a comprehensive report outlining the technical,
operational, and infrastructural dimensions of the project.
Following the discussions, it was
decided that the company would conduct a more detailed feasibility study,
adhering to scientific standards and implementation requirements, while
considering the physical space needed for project execution. The findings will be
submitted to the Organization’s expert working group for further review.
Concurrently, the Organization’s Economic Affairs Department will carry out a
financial and economic analysis of the initiative, with results to be presented
in upcoming sessions.
The meeting also included in-depth
evaluations by technical experts regarding the required equipment, operational
processes, and implementation framework.
Designed to enhance national capacity
in blood-derived products and strengthen the country’s medical infrastructure,
the project will continue to undergo expert assessment in the coming weeks
under the supervision of the Organization’s specialized committees.